$2.89 Billion is the total value of Boxer Capital, LLC's 75 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MRTX | MIRATI THERAPEUTICS INC | $293,171,000 | +45.4% | 1,765,560 | 0.0% | 10.13% | +14.3% | |
| SWTX | SPRINGWORKS THERAPEUTICS INC | $98,958,000 | +13.5% | 2,075,905 | 0.0% | 3.42% | -10.8% | |
| SGEN | SEATTLE GENETICS INC | $78,276,000 | +15.2% | 400,000 | 0.0% | 2.70% | -9.5% | |
| SAGE | SAGE THERAPEUTICS INC | $66,865,000 | +47.0% | 1,094,000 | 0.0% | 2.31% | +15.6% | |
| BDTX | BLACK DIAMOND THERAPEUTICS I | $60,909,000 | -28.3% | 2,014,858 | 0.0% | 2.10% | -43.6% | |
| ALLK | ALLAKOS INC | $54,979,000 | +13.3% | 675,000 | 0.0% | 1.90% | -10.9% | |
| ARGX | ARGENX SEsponsored adr | $44,871,000 | +16.6% | 170,926 | 0.0% | 1.55% | -8.4% | |
| CGEN | COMPUGEN LTDord | $38,735,000 | +8.2% | 2,383,673 | 0.0% | 1.34% | -14.9% | |
| ESPR | ESPERION THERAPEUTICS INC NE | $36,241,000 | -27.6% | 975,000 | 0.0% | 1.25% | -43.1% | |
| RCUS | ARCUS BIOSCIENCES INC | $35,735,000 | -30.7% | 2,084,883 | 0.0% | 1.24% | -45.5% | |
| SNDX | SYNDAX PHARMACEUTICALS INC | $33,768,000 | -0.4% | 2,287,782 | 0.0% | 1.17% | -21.7% | |
| RCKT | ROCKET PHARMACEUTICALS INC | $33,514,000 | +9.2% | 1,466,051 | 0.0% | 1.16% | -14.2% | |
| FOLD | AMICUS THERAPEUTICS INC | $32,829,000 | -6.4% | 2,325,000 | 0.0% | 1.13% | -26.4% | |
| GOSS | GOSSAMER BIO INC | $31,799,000 | -4.5% | 2,562,358 | 0.0% | 1.10% | -24.9% | |
| RNA | AVIDITY BIOSCIENCES INC | $31,565,000 | -0.4% | 1,121,327 | 0.0% | 1.09% | -21.7% | |
| AMRN | AMARIN CORP PLCspons adr new | $29,470,000 | -39.2% | 7,000,000 | 0.0% | 1.02% | -52.2% | |
| QURE | UNIQURE NV | $28,190,000 | -18.3% | 765,400 | 0.0% | 0.97% | -35.8% | |
| IDYA | IDEAYA BIOSCIENCES INC | $27,667,000 | -11.6% | 2,202,812 | 0.0% | 0.96% | -30.5% | |
| PASG | PASSAGE BIO INC | $25,280,000 | -52.0% | 1,928,315 | 0.0% | 0.87% | -62.3% | |
| KDMN | KADMON HLDGS INC | $24,327,000 | -23.4% | 6,205,882 | 0.0% | 0.84% | -39.8% | |
| ANAB | ANAPTYSBIO INC | $19,175,000 | -34.0% | 1,300,000 | 0.0% | 0.66% | -48.1% | |
| BMRN | BIOMARIN PHARMACEUTICAL INC | $19,020,000 | -38.3% | 250,000 | 0.0% | 0.66% | -51.5% | |
| CABA | CABALETTA BIO INC | $16,979,000 | -2.6% | 1,566,361 | 0.0% | 0.59% | -23.4% | |
| AGEN | AGENUS INC | $16,000,000 | +1.8% | 4,000,000 | 0.0% | 0.55% | -20.0% | |
| ACAD | ACADIA PHARMACEUTICALS INC | $15,263,000 | -14.9% | 370,000 | 0.0% | 0.53% | -33.1% | |
| CLDX | CELLDEX THERAPEUTICS INC NEW | $14,830,000 | +14.1% | 1,000,000 | 0.0% | 0.51% | -10.5% | |
| GBT | GLOBAL BLOOD THERAPEUTICS IN | $13,785,000 | -12.7% | 250,000 | 0.0% | 0.48% | -31.4% | |
| PRVL | PREVAIL THERAPEUTICS INC | $11,433,000 | -31.7% | 1,123,105 | 0.0% | 0.40% | -46.3% | |
| RLMD | RELMADA THERAPEUTICS INC | $11,286,000 | -15.9% | 300,000 | 0.0% | 0.39% | -33.9% | |
| MREO | MEREO BIOPHARMA GROUP PLCads | $10,558,000 | -14.4% | 4,029,649 | 0.0% | 0.36% | -32.7% | |
| MEIP | MEI PHARMA INC | $9,089,000 | -24.5% | 2,913,091 | 0.0% | 0.31% | -40.6% | |
| MTNB | MATINAS BIOPHARMA HLDGS INC | $8,793,000 | -0.9% | 11,478,634 | 0.0% | 0.30% | -22.1% | |
| SELB | SELECTA BIOSCIENCES INC | $8,144,000 | -12.7% | 3,284,072 | 0.0% | 0.28% | -31.5% | |
| ZYME | ZYMEWORKS INC | $7,686,000 | +29.1% | 165,000 | 0.0% | 0.27% | +1.5% | |
| XENE | XENON PHARMACEUTICALS INC | $6,642,000 | -11.7% | 600,000 | 0.0% | 0.23% | -30.5% | |
| MIRM | MIRUM PHARMACEUTICALS INC | $6,109,000 | -1.0% | 317,000 | 0.0% | 0.21% | -22.1% | |
| FULC | FULCRUM THERAPEUTICS INC | $5,598,000 | -56.6% | 705,882 | 0.0% | 0.19% | -66.0% | |
| KNSA | KINIKSA PHARMACEUTICALS LTD | $4,452,000 | -39.9% | 290,577 | 0.0% | 0.15% | -52.8% | |
| LSACU | LIFESCI ACQUISITION CORPunit 03/31/2025 | $4,080,000 | +36.5% | 300,000 | 0.0% | 0.14% | +7.6% | |
| AGLE | AEGLEA BIOTHERAPEUTICS INC | $3,900,000 | -23.3% | 550,000 | 0.0% | 0.14% | -39.7% | |
| LJPC | LA JOLLA PHARMACEUTICAL CO | $3,590,000 | -5.4% | 890,700 | 0.0% | 0.12% | -25.7% | |
| SLDB | SOLID BIOSCIENCES INC | $3,110,000 | -30.7% | 1,531,872 | 0.0% | 0.11% | -45.7% | |
| CLRB | CELLECTAR BIOSCIENCES INC | $1,141,000 | -3.1% | 920,000 | 0.0% | 0.04% | -25.0% | |
| ZGNX | ZOGENIX INC | $489,000 | -33.6% | 27,300 | 0.0% | 0.02% | -46.9% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2020-11-17
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MIRATI THERAPEUTICS INC | 32 | Q3 2023 | 55.2% |
| BEIGENE LTD | 31 | Q3 2023 | 15.6% |
| KURA ONCOLOGY INC. | 24 | Q3 2021 | 4.7% |
| ROCKET PHARMACEUTICALS INC | 23 | Q3 2023 | 5.4% |
| DBV TECHNOLOGIES S A | 23 | Q3 2023 | 3.9% |
| MEI PHARMA INC | 21 | Q2 2023 | 1.4% |
| SYNDAX PHARMACEUTICALS INC | 20 | Q3 2021 | 3.1% |
| GOSSAMER BIO INC | 19 | Q3 2023 | 4.7% |
| ODONATE THERAPEUTICS INC | 18 | Q1 2022 | 12.5% |
| ESPERION THERAPEUTICS INC NE | 18 | Q2 2021 | 11.0% |
View Boxer Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| IDEAYA Biosciences, Inc. | February 14, 2023 | 2,202,812 | 4.6% |
| Milestone Pharmaceuticals Inc. | February 14, 2023 | 698,861 | 2.0% |
| SpringWorks Therapeutics, Inc. | September 19, 2022 | 3,421,541 | 5.7% |
| iTeos Therapeutics, Inc. | May 11, 2022 | 2,154,058 | 6.1% |
| Atreca, Inc. | February 14, 2022 | 2,202,333 | 7.2% |
| Biomea Fusion, Inc. | February 14, 2022 | 1,188,405 | 4.1% |
| Cabaletta Bio, Inc. | February 14, 2022 | 540,000 | 1.9% |
| CymaBay Therapeutics, Inc. | February 14, 2022 | ? | ? |
| DBV Technologies S.A. | February 14, 2022 | 1,067,299 | 1.9% |
| Elevation Oncology, Inc. | February 14, 2022 | 872,780 | 3.8% |
View Boxer Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-12 |
| 4 | 2024-02-08 |
| SC 13D/A | 2024-02-08 |
| 4 | 2024-01-25 |
| SC 13D/A | 2024-01-25 |
| SC 13G | 2024-01-18 |
| SC 13D/A | 2023-12-18 |
View Boxer Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.